Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 11/20 | 0.32 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1989938 | 0.87 | RHOC (0.41) | F2NPC1RAB9A | |
| SCHEMBL1551036 | 0.85 | CNR1 (0.38) | BACE1BACE2 | |
| SCHEMBL1989761 | 0.85 | BACE1 (0.38) | BACE1BACE2IDO1 | |
| SCHEMBL1987375 | 0.84 | GRM5 (0.47) | NPC1RAB9A | |
| SCHEMBL977151 | 0.83 | ERAP1 (0.37) | F2BACE1BACE2 | |
| SCHEMBL1988810 | 0.83 | CLK1 (0.37) | NPC1RAB9ABACE1BACE2 | |
| SCHEMBL1988739 | 0.82 | CYP3A4 (0.45) | BACE1BACE2 | |
| SCHEMBL974838 | 0.82 | F2 (0.34) | F2BACE1BACE2IDO1 | |
| SCHEMBL974739 | 0.82 | F2 (0.34) | F2BACE1BACE2IDO1 | |
| SCHEMBL3401743 | 0.82 | BACE1 (0.37) | F2BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152236-A1 | AZETIDINE POLYSUBSTITUTED COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2011-06-23 | — | — | US | claimed |
| US-20110152236-A1 | AZETIDINE POLYSUBSTITUTED COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152236-A1 | AZETIDINE POLYSUBSTITUTED COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | C1R, TACR1, C1S | F2 1930/4885NPC1 153/4885RAB9A 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.